Pluristem Life Systems, Inc. has announced that it has entered into a Collaborative Research Agreement with the Berlin-Brandenburg Center for Regenerative Therapy (BCRT) at Charite - University Medicine Berlin.
Pluristem and BCRT will collaborate on a variety of indications utilizing mesenchymal stem cells (MSCs) derived from the placenta that have been expanded in the Company’s PluriX™ 3-D bioreactor. The initial focus of the collaboration will be on neurological indications such as Multiple Sclerosis and Parkinson’s disease.
The agreement also covers organ transplantation and cardiovascular indications such as inflammatory cardiomyopathy. Pluristem will be the exclusive owner of the technology and any products stemming from the collaboration.
Professor Hans Dieter Volk, MD, Director/ Chairman of BCRT at Charité commented, “The collaboration of BCRT, working with Pluristem and their proprietary PLX cells offers several exciting prospects. We believe Pluristem’s cells can potentially result in beneficial therapies for a number of diseases.”
The BCRT is a cooperative research institution of the Charité University Hospital in Berlin and Germany’s largest research association, the Helmholtz Association.
“This cooperation is extremely important to us,” commented Pluristem Chairman and CEO, Mr. Zami Aberman. “First, it corroborates our approach regarding the use of MSCs from the placenta and our PluriX™ technology to develop new therapeutic products for a variety of indications. In addition, the collaboration significantly enhances our approach to develop our pipe line of products.”